EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560

Kieran W Benn iD, Patrick H Yuan, Harvey K Chong, Stanley S Stylii, Rodney B Luwor, Christopher R French iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0309438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Kieran W Benn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neural Dynamics Laboratory, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Astrocytoma, Cell Movement, Cell Proliferation, Ether-A-Go-Go Potassium Channels. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gliomas are highly malignant brain tumours that remain refractory to treatment. Treatment is typically surgical intervention followed by concomitant temozolomide and radiotherapy; however patient prognosis remains poor. Voltage gated ion channels have emerged as novel targets in cancer therapy and inhibition of a potassium selective subtype (hERG, Kv11.1) has demonstrated antitumour activity. Unfortunately blockade of hERG has been limited by cardiotoxicity, however hERG channel agonists have produced similar chemotherapeutic benefit without significant side effects. In this study, electrophysiological recordings suggest the presence of hERG channels in the anaplastic astrocytoma cell line SMA-560, and treatment with the hERG channel agonist NS1643, resulted in a significant reduction in the proliferation of SMA-560 cells. In addition, NS1643 treatment also resulted in a reduction of the secretion of matrix metalloproteinase-9 and SMA-560 cell migration. When combined with temozolomide, an additive impact was observed, suggesting that NS1643 may be a suitable adjuvant to temozolomide and limit the invasiveness of glioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstrocytomaCell MovementCell ProliferationEther-A-Go-Go Potassium ChannelsTemozolomideMatrix Metalloproteinase 9HumansCell Line, TumorNeoplasm InvasivenessDacarbazineERG1 Potassium ChannelAntineoplastic AgentsBrain NeoplasmsCresolsPhenylurea Compounds

Substanzen

Ether-A-Go-Go Potassium ChannelsTemozolomideMatrix Metalloproteinase 91,3-bis(2-hydroxy-5-trifluoromethylphenyl)ureaDacarbazineERG1 Potassium ChannelKCNH2 protein, humanAntineoplastic AgentsCresolsPhenylurea Compounds

Autor:innen und Institutionen

  • Neural Dynamics Laboratory, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Neurosurgery, Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia.
  • Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Kieran W Benn, Christopher R French

Zitieren

APA

Benn, K. W., Yuan, P. H., Chong, H. K., Stylii, S. S., Luwor, R. B., & French, C. R. (2024). hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560. PLOS ONE. https://doi.org/10.1371/journal.pone.0309438

Vancouver

Benn KW, Yuan PH, Chong HK, Stylii SS, Luwor RB, French CR. hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560. PLOS ONE. 2024. doi:10.1371/journal.pone.0309438

BibTeX
@article{Benn2024,
  author = {Benn, Kieran W and Yuan, Patrick H and Chong, Harvey K and Stylii, Stanley S and Luwor, Rodney B and French, Christopher R},
  title = {hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0309438}
}
Kostenlos starten →